Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JNJ-64052781 |
Trade Name | |
Synonyms | Duvortuxizumab|MGD011 |
Drug Descriptions |
JNJ-64052781 (duvortuxizumab) is an antibody-like protein that binds to both CD3 and CD19, resulting in cross-linking of tumor B-cells and cytotoxic T-lymphocytes, potentially leading to immune response against B-cell malignancies (NCI Drug Dictionary). |
DrugClasses | CD19 Antibody 21 |
CAS Registry Number | 1831098-91-9 |
NCIT ID | C122406 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ibrutinib + JNJ-64052781 | Ibrutinib JNJ-64052781 | 0 | 1 |
JNJ-64052781 | JNJ-64052781 | 0 | 1 |